Evaluation of the High Dose of Icotinib in Advanced Lung Cancer Patients After Failure of Target Therapy
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of dose escalation of
Icotinib in advanced non small cell lung cancer (NSCLC) patients after the therapy of
Icotinib, Iressa and Tarceva.